Company profile
Opus Genetics, Inc.
Pipeline8 assets
- OPGx-LCA5OPGx-LCA5 / LCA5 / AAV Gene Therapy / OphthalmologyLeber Congenital Amaurosis Type 5 (LCA5)
- OPGx-BEST1OPGx-BEST1 / BEST1 / AAV Gene Therapy / OphthalmologyBest Vitelliform Macular Dystrophy (BVMD)Autosomal Recessive Bestrophinopathy (ARB)
- OPGx-RDH12OPGx-RDH12 / RDH12 / AAV Gene Therapy / OphthalmologyRDH12-associated Leber Congenital Amaurosis (RDH12-LCA)
- OPGx-MERTKOPGx-MERTK / MERTK / AAV Gene Therapy / OphthalmologyMERTK-associated Retinitis Pigmentosa
- OPGx-RHOOPGx-RHO / RHO / AAV Gene Therapy / OphthalmologyAutosomal Dominant Retinitis Pigmentosa (RHO-adRP)
- OPGx-CNGB1OPGx-CNGB1 / CNGB1 / AAV Gene Therapy / OphthalmologyCNGB1-associated Inherited Retinal Diseases
- OPGx-NMNAT1OPGx-NMNAT1 / NMNAT1 / AAV Gene Therapy / OphthalmologyNMNAT1-associated Inherited Retinal Diseases
- Phentolamine Ophthalmic Solution 0.75%Small Molecule / OphthalmologyPharmacologically induced mydriasisPresbyopiaLow-light visual disturbances following keratorefractive surgery
Latest news17 items
All newsOpus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
Trial Results • Phase 1/2OPGx-BEST1 Cohort 1 topline data Tue, Sep 1, 2026, 10:00 AM ET
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
Presentation / Abstract • Phase 1/2
Opus Genetics to Participate in Leading Medical Conferences in May 2026
Presentation / Abstract • Phase 1
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Presentation / Abstract • Phase 3
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
Presentation / Abstract • Phase 1/2
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
Presentation / Abstract • Phase 1/2
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Presentation / Abstract • Phase 1